What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Surgery
Shamir R. Mehta focuses on Myocardial infarction, Internal medicine, Cardiology, Percutaneous coronary intervention and Acute coronary syndrome.
His Myocardial infarction research includes themes of Anesthesia, Randomized controlled trial, Surgery, Angioplasty and Stroke.
His Anesthesia research includes elements of Placebo and Elinogrel.
The Cardiology study combines topics in areas such as Insulin and Pharmacology.
His Percutaneous coronary intervention study incorporates themes from Heparin, Radial artery, Conventional PCI and Femoral artery.
His work in Acute coronary syndrome addresses issues such as Enoxaparin sodium, which are connected to fields such as Proportional hazards model.
His most cited work include:
- Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. (5461 citations)
- Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. (2715 citations)
- Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. (1357 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Cardiology, Myocardial infarction, Percutaneous coronary intervention and Acute coronary syndrome.
His research on Internal medicine frequently connects to adjacent areas such as Surgery.
His Cardiology research integrates issues from Fibrinolysis and Heparin.
His Myocardial infarction study integrates concerns from other disciplines, such as Coronary artery disease and Hazard ratio.
He studied Percutaneous coronary intervention and Conventional PCI that intersect with Emergency medicine.
His research investigates the connection with Clopidogrel and areas like Anesthesia which intersect with concerns in Placebo.
He most often published in these fields:
- Internal medicine (85.41%)
- Cardiology (68.38%)
- Myocardial infarction (62.70%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (85.41%)
- Myocardial infarction (62.70%)
- Cardiology (68.38%)
In recent papers he was focusing on the following fields of study:
Shamir R. Mehta mostly deals with Internal medicine, Myocardial infarction, Cardiology, Percutaneous coronary intervention and Conventional PCI.
His Internal medicine and Coronary artery disease, Randomized controlled trial, Ticagrelor, Acute coronary syndrome and Aspirin investigations all form part of his Internal medicine research activities.
His study in Myocardial infarction focuses on Mace in particular.
The Revascularization, ST segment and Heart failure research Shamir R. Mehta does as part of his general Cardiology study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
His Percutaneous coronary intervention research is multidisciplinary, incorporating perspectives in Stent, Surgery and Hazard ratio.
His research investigates the link between Conventional PCI and topics such as Emergency medicine that cross with problems in Cognitive impairment.
Between 2018 and 2021, his most popular works were:
- Ticagrelor with or without Aspirin in High-Risk Patients after PCI (255 citations)
- Complete Revascularization with Multivessel PCI for Myocardial Infarction (187 citations)
- Ticagrelor in Patients with Stable Coronary Disease and Diabetes (97 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
